Analysis of healthcare utilization before the diagnosis of radiologically isolated syndrome
Lebrun-Frenay C, Kerbrat S, Okuda DT, Landes-Chateau C, Kantarci OH, Pierret C, Drezen E, Nowak E, Siva A, Azevedo CJ, Cohen M, Leray E 2025 Feb 31 184-196Time to move past typical syndromes in the diagnosis of multiple sclerosis
Lebrun-Frenay C, Okuda DT 2024 Oct 30 1570-1572Underdosed generic specialty medications: A prescription for patient harm?
Okuda DT, Burgess KW, Moog TM, Patel MA 2024 Aug 88Radiologically isolated syndrome in the spectrum of multiple sclerosis
Okuda DT 2024 May 30 630-636The diagnostic value of the central vein sign in radiologically isolated syndrome
Landes-Chateau C, Levraut M, Okuda DT, Themelin A, Cohen M, Kantarci OH, Siva A, Pelletier D, Mondot L, Lebrun-Frenay C 2024 Mar 11 662-672Reply: Do we need new MRI criteria for the diagnosis of radiologically isolated syndrome?
Lebrun-Frenay C, Kantarci OH, Siva A, Pelletier D, Okuda DT 2023 Nov 146 E104-E106The radiologically isolated syndrome: revised diagnostic criteria
Author Collaboration TR, Lebrun-Frénay C, Okuda DT, Siva A, Landes-Chateau C, Azevedo CJ, Mondot L, Carra-Dallière C, Zephir H, Louapre C, Durand-Dubief F, Le Page E, Bensa C, Ruet A, Ciron J, Laplaud DA, Casez O, Mathey G, De Seze J, Zeydan B, Makhani N, Tutuncu M, Levraut M, Cohen M, Thouvenot E, Pelletier D, Kantarci OH 2023 Aug 146 3431-3443Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Yes
Lebrun-Frenay C, Okuda DT 2023 Jun 29 793-795Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome
Okuda DT, Kantarci O, Lebrun-Frénay C, Sormani MP, Azevedo CJ, Bovis F, Hua LH, Amezcua L, Mowry EM, Hotermans C, Mendoza J, Walsh JS, von Hehn C, Vargas WS, Donlon S, Naismith RT, Okai A, Pardo G, Repovic P, Stüve O, Siva A, Pelletier D 2023 Mar 93 604-614Factors associated with the misdiagnosis of neuromyelitis optica spectrum disorder
Smith AD, Moog TM, Burgess KW, McCreary M, Okuda DT 2023 Feb 70Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension study
Okuda DT, Kantor D, Jaros M, Devries T, Hunter S 2023 5From the prodromal stage of multiple sclerosis to disease prevention
Marrie RA, Allegretta M, Barcellos LF, Bebo B, Calabresi PA, Correale J, Davis B, De Jager PL, Gasperi C, Greenbaum C, Helme A, Hemmer B, Kanellis P, Kostich W, Landsman D, Lebrun-Frenay C, Makhani N, Munger KL, Okuda DT, Ontaneda D, Postuma RB, Quandt JA, Roman S, Saidha S, Sormani MP, Strum J, Valentine P, Walton C, Zackowski KM, Zhao Y, Tremlett H 2022 Sep 18 559-572Editorial: Understanding the concept of pre-clinical autoimmunity
Olsen NJ, Okuda DT, Holers VM, Karp DR 2022 Jul 13Outcome measures assisting treatment optimization in multiple sclerosis
Pardo G, Coates S, Okuda DT 2022 Mar 269 1282-1297Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event
Lebrun-Frenay C, Kantarci O, Siva A, Sormani MP, Pelletier D, Okuda DT, Azevedo C, Amato MP, Bensa C, Berger E, Brochet B, Ciron J, Cohen M, Inglese M, Keegan BM, Labauge P, Laplaud DA, Le Page E, Louapre C, Makhani N, Mathey G, Mondot L, Montalban X, Pelletier J, de Seze J, deStefano N, Thouvenot E, Tintore M, Tutuncuoglu M, Uygunoglu U, Vermersch P, Weinshenker B, Zeydan B 2020 Aug 88 407-417Limitations of cell-lineage-specific non-dynamic gene recombination in CD11c.Cre+ITGA4fl/fl mice
Manouchehri N, Hussain RZ, Cravens PD, Doelger R, Greenberg BM, Okuda DT, Forsthuber TG, Eagar TN, Stüve O 2020 Jul 344Handedness and potential implications for neurorehabilitation in multiple sclerosis
Shirani A, Okuda DT 2020 Jan 37Atypical Neuromyelitis Optica Spectrum Disorder With Diffuse Cerebral Abnormalities: A Case Report
Newton BD, Kantarci O, Okuda DT 2020 12Baseline cerebral metabolism predicts fatigue and cognition in Multiple Sclerosis patients
West K, Sivakolundu D, Maruthy G, Zuppichini M, Liu P, Thomas B, Spence J, Lu H, Okuda D, Rypma B 2020 27α4-integrin deficiency in B cells does not affect disease in a T-cell-mediated EAE disease model
Hussain RZ, Cravens PD, Miller-Little WA, Doelger R, Granados V, Herndon E, Okuda DT, Eagar TN, Stüve O 2019 Jul 6Leveraging technology to identify subclinical deficits in radiologically isolated syndrome
Okuda D 2019 Jan 26 3-4Body mass index, but not Vitamin D status, is associated with brain volume change in MS
Mowry EM, Azevedo CJ, McCulloch CE, Okuda D, Lincoln RR, Waubant E, Hauser SL, Pelletier D 2018 Dec 91 E2256-E2264TLR3 agonism re-establishes CNS immune competence during α4-integrin deficiency
Hussain RZ, Cravens PC, Doelger R, Dentel B, Herndon E, Loof N, Tsai P, Okuda D, Racke MK, Stuve O 2018 Dec 5 1543-1561Precision medicine for multiple sclerosis promotes preventative medicine
Hansen MR, Okuda DT 2018 May 1420 62-71Cervical spinal cord atrophy: An earlymarker of progressiveMSonset
Zeydan B, Gu X, Atkinson EJ, Keegan BM, Weinshenker BG, Tillema JM, Pelletier D, Azevedo CJ, Lebrun-Frenay C, Siva A, Okuda DT, Kantarci K, Kantarci OH 2018 Mar 5Anomalies Characteristic of Central Nervous System Demyelination: Radiologically Isolated Syndrome
Author Collaboration R, Lebrun C, Kantarci OH, Siva A, Pelletier D, Okuda DT 2018 Feb 36 59-68Radiologically isolated syndrome should be treated with disease-modifying therapy – Yes
Okuda DT 2017 Dec 23 1818-1819Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation
Wright K, Winkler MD, Newton BD, Sormani MP, Okuda DT 2017 Oct 4Finger tapping impairments are highly sensitive for evaluating upper motor neuron lesions
Shirani A, Newton BD, Okuda DT 2017 Mar 17Are miRNAs appropriate biomarkers for radiologic measures of tissue injury in multiple sclerosis?
Okuda DT 2017 Mar 74 260-261Long-term evolution of multiple sclerosis disability in the treatment era
Author Collaboration Uo, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Büdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL 2016 Oct 80 499-510Long-term evolution of multiple sclerosis disability in the treatment era
Author Collaboration Uo, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Büdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL 2016 Oct 80 499-510Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders
Lebrun C, Cohen M, Pignolet B, Seitz-Polski B, Bucciarelli F, Benzaken S, Kantarci O, Siva A, Okuda D, Pelletier D, Brassat D 2016 Sep 368 334-336Primary Progressive Multiple Sclerosis Evolving from Radiologically Isolated Syndrome
Kantarci OH, Lebrun C, Siva A, Keegan MB, Azevedo CJ, Inglese M, Tintoré M, Newton BD, Durand-Dubief F, Amato MP, De Stefano N, Sormani MP, Pelletier D, Okuda DT 2016 Feb 79 288-294Extended interval dosing of natalizumab in multiple sclerosis
Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, Pandey K, Donnelly S, Pawate S, Bomprezzi R, Smith D, Kolb C, Qureshi S, Okuda D, Kalina J, Rimler Z, Green R, Monson NL, Hoyt T, Bradshaw M, Fallon J, Chamot E, Bucello M, Beh SC, Cutter G, Major E, Herbert J, Frohman E 2016 Jan 87 885-889Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis
Shirani A, Okuda DT, Stüve O 2016 Jan 13 58-69Aquatic training in MS: Neurotherapeutic impact upon quality of life
Frohman AN, Okuda D, Beh SC, Treadaway K, Mooi C, Davis SL, Shah A, Frohman TC, Frohman E 2015 Aug 2 864-872Early CNS neurodegeneration in radiologically isolated syndrome
Azevedo CJ, Overton E, Khadka S, Buckley J, Liu S, Sampat M, Kantarci O, Frenay CL, Siva A, Okuda DT, Pelletier D 2015 Jun 2 e102Pontine myelinolysis following excessive consumption of commercial energy drinks
Newton BD, Okuda DT 2015 Jun 2 e91Central neuropathic pain in MS is due to distinct thoracic spinal cord lesions
Okuda DT, Melmed K, Matsuwaki T, Blomqvist A, Craig AD 2014 Aug 1 554-561In vivo evidence of glutamate toxicity in multiple sclerosis
Azevedo CJ, Kornak J, Chu P, Sampat M, Okuda DT, Cree BA, Nelson SJ, Hauser SL, Pelletier D 2014 Aug 76 269-278Radiologically isolated syndrome: 5-year risk for an initial clinical event
Okuda DT, Siva A, Kantarci O, Inglese M, Katz I, Tutuncu M, Keegan BM, Donlon S, Hua LH, Vidal-Jordana A, Montalban X, Rovira A, Tintoré M, Amato MP, Brochet B, De Seze J, Brassat D, Vermersch P, De Stefano N, Sormani MP, Pelletier D, Lebrun C 2014 Mar 9A case of Susac syndrome with cervical spinal cord involvement on MRI
Hua LH, Donlon SL, Okuda DT 2014 Feb 337 228-231Metabolite changes in radiologically isolated syndrome: More pathology than meets the eye?
Okuda DT, Vrenken H 2013 Jun 80 2084-2085Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis
Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, Gourraud PA, Brenneman D, Owen MC, Qualley P, Bucci M, Hauser SL, Pelletier D 2012 Aug 72 234-240From injection therapies to natalizumab: Views on the treatment of multiple sclerosis
Bomprezzi R, Okuda D, Alderazi YJ, Stüve O, Frohman E 2012 Mar 5 97-104Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome
Okuda DT, Mowry EM, Cree BA, Crabtree EC, Goodin DS, Waubant E, Pelletier D 2011 Feb 76 686-692Switching multiple sclerosis patients with breakthrough disease to second-line therapy
Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree BA, Goodin DS, Green AJ, Okuda DT, Pelletier D, Zamvil SS, Vittinghoff E, Waubant E 2011 6Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis
Baranzini SE, Srinivasan R, Khankhanian P, Okuda DT, Nelson SJ, Matthews PM, Hauser SL, Oksenberg JR, Pelletier D 2010 Sep 133 2603-2611Recurrent asymptomatic demyelinating disease following 13-cis-retinoic acid exposure
Okuda DT, Prados MD 2009 SepConnecting white matter injury and thalamic atrophy in clinically isolated syndromes
Henry RG, Shieh M, Amirbekian B, Chung S, Okuda DT, Pelletier D 2009 Jul 282 61-66Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures
Mowry EM, Beheshtian A, Waubant E, Goodin DS, Cree BA, Qualley P, Lincoln R, George MF, Gomez R, Hauser SL, Okuda DT, Pelletier D 2009 May 72 1760-1765Incidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome
Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, Hauser SL, Pelletier D 2009 Mar 72 800-805Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis
Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, Radue EW, Lindberg RL, Uitdehaag BM, Johnson MR, Angelakopoulou A, Hall L, Richardson JC, Prinjha RK, Gass A, Geurts JJ, Kragt J, Sombekke M, Vrenken H, Qualley P, Lincoln RR, Gomez R, Caillier SJ, George MF, Mousavi H, Guerrero R, Okuda DT, Cree BA, Green AJ, Waubant E, Goodin DS, Pelletier D, Matthews PM, Hauser SL, Kappos L, Polman CH, Oksenberg JR 2009 18 767-778Regional grey matter atrophy in clinically isolated syndromes at presentation
Henry RG, Shieh M, Okuda DT, Evangelista A, Gorno-Tempini ML, Pelletier D 2008 Nov 79 1236-1244Naegleria fowleri hemorrhagic meningoencephalitis: Report of two fatalities in children
Okuda DT, Hanna HJ, Coons SW, Bodensteiner JB 2004 Mar 19 231-233Arterial thrombosis induced by IVIg and its treatment with tPA
Okuda D, Flaster M, Frey J, Sivakumar K 2003 Jun 60 1825-1826